BIOA Cash-Secured Put Strategy

BIOA (BioAge Labs, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

BIOA (BioAge Labs, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $720.6M, a beta of 1.00 versus the broader market, a 52-week range of 3.67-24, average daily share volume of 489K, a public-listing history dating back to 2024, approximately 62 full-time employees. These structural characteristics shape how BIOA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.00 places BIOA roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a cash-secured put on BIOA?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

Current BIOA snapshot

As of May 15, 2026, spot at $17.45, ATM IV 85.90%, IV rank 11.09%, expected move 24.63%. The cash-secured put on BIOA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this cash-secured put structure on BIOA specifically: BIOA IV at 85.90% is on the cheap side of its 1-year range, which means a premium-selling BIOA cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 24.63% (roughly $4.30 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BIOA expiries trade a higher absolute premium for lower per-day decay. Position sizing on BIOA should anchor to the underlying notional of $17.45 per share and to the trader's directional view on BIOA stock.

BIOA cash-secured put setup

The BIOA cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BIOA near $17.45, the first option leg uses a $16.58 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BIOA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BIOA shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$16.58N/A

BIOA cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

BIOA cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on BIOA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on BIOA

Cash-secured puts on BIOA earn premium while a trader waits to acquire BIOA stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning BIOA.

BIOA thesis for this cash-secured put

The market-implied 1-standard-deviation range for BIOA extends from approximately $13.15 on the downside to $21.75 on the upside. A BIOA cash-secured put lets a trader earn premium while waiting to acquire BIOA at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current BIOA IV rank near 11.09% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BIOA at 85.90%. As a Healthcare name, BIOA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BIOA-specific events.

BIOA cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BIOA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BIOA alongside the broader basket even when BIOA-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on BIOA carry tail risk when realized volatility exceeds the implied move; review historical BIOA earnings reactions and macro stress periods before sizing. Always rebuild the position from current BIOA chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on BIOA?
A cash-secured put on BIOA is the cash-secured put strategy applied to BIOA (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With BIOA stock trading near $17.45, the strikes shown on this page are snapped to the nearest listed BIOA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are BIOA cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the BIOA cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 85.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a BIOA cash-secured put?
The breakeven for the BIOA cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BIOA market-implied 1-standard-deviation expected move is approximately 24.63%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on BIOA?
Cash-secured puts on BIOA earn premium while a trader waits to acquire BIOA stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning BIOA.
How does current BIOA implied volatility affect this cash-secured put?
BIOA ATM IV is at 85.90% with IV rank near 11.09%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related BIOA analysis